Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/14/2025

Hemophilia Management

Introduction to Hemophilia

  • Hemophilia A severity is classified based on factor VIII activity levels: severe (<1%), moderate (1-5%), or mild (>5% to <40% of normal), which correlates with clinical bleeding patterns and guides treatment decisions, as defined by the World Federation of Hemophilia 1, 2
  • The prevalence of hemophilia A is approximately 1 in 5,000 males, primarily affecting males due to its X-linked recessive disorder nature, according to the American Academy of Pediatrics 3
  • Females with low factor VIII activity may experience excessive bleeding after trauma or surgery, menorrhagia, postpartum hemorrhage, and spontaneous bleeding in severe cases, as reported by the American College of Obstetricians and Gynecologists 4

Diagnosis and Assessment

  • The severity of Factor VIII deficiency correlates with the degree of PTT prolongation, as classified by the International Society on Thrombosis and Haemostasis:

    Severity Factor VIII Activity Level PTT Prolongation
    Severe <1% of normal Markedly prolonged
    Moderate 1-5% of normal Moderately prolonged
    Mild >5% to <40% of normal Mildly prolonged or normal

    3

  • Clot Waveform Analysis (CWA) is an enhanced APTT-based technique that provides additional information and can detect very low levels of FVIII/FIX activity that conventional assays might miss, particularly useful in severe hemophilia, as reported by the Journal of Thrombosis and Haemostasis 5
  • Thrombin Generation Assay can detect hypocoagulability from factor VIII or IX deficiency and is useful for monitoring hemostatic therapies, according to the Journal of Thrombosis and Haemostasis 6
  • The Bethesda assay is the definitive test for quantifying FVIII inhibitors, which quantifies FVIII inhibitors by measuring their ability to neutralize FVIII activity, with one Bethesda Unit defined as the amount of inhibitor that neutralizes 50% of FVIII activity in normal plasma, as recommended by the International Society on Thrombosis and Haemostasis 2
  • Clinically significant inhibitor levels are ≥0.6 Bethesda Units/mL on two separate occasions, with a strength of evidence level of moderate, according to the International Society on Thrombosis and Haemostasis 1, 2

Prophylaxis and Treatment

  • Emicizumab, a FVIII-mimetic bispecific antibody, is approved for prophylaxis in patients with or without inhibitors, and is administered subcutaneously every 1-2 weeks, with Factor VIII replacement still required for breakthrough bleeding, as recommended by the American Society of Hematology 7
  • Valoctocogene roxaparvovec, an AAV vector-based gene therapy, shows promise for providing long-term endogenous FVIII production by transferring functional F8 genetic information into hepatocytes, according to the National Hemophilia Foundation 7
  • The initial bolus dose of factor VIII concentrate is 20-50 IU/kg, and subsequent doses are 20-50 IU/kg every 6-8 hours or continuous infusion (3-4 IU/kg/h), based on the severity of contusion and baseline factor VIII level, as recommended by the Haematologica guideline society 2
  • For patients with inhibitors, bypassing agents such as recombinant activated factor VII (rFVIIa) or activated prothrombin complex concentrate (aPCC) should be used instead of factor VIII, with dosages of 46-150 mcg/kg every 2-24 hours or 50-100 IU/kg every 8-12 hours, respectively 2
  • Treatment with factor VIII concentrate should be continued until bleeding is controlled, typically 24-72 hours for minor injuries, as recommended by the Haematologica guideline society 2
  • Factor replacement therapy is based on severity and clinical situation, and the presence of inhibitors requires alternative treatment strategies, including bypassing agents and immunosuppressive therapy, as recommended by the National Hemophilia Foundation and the American Society of Hematology 1, 2, 8

Invasive Procedures and Dental Care

  • Mandatory factor replacement is required for invasive procedures such as extractions, periodontal surgery, endodontic surgery, and implant placement, and a protocol should be followed, including consulting a hematologist for factor replacement protocol, administering factor replacement immediately before the procedure, and maintaining factor levels for 7-10 days post-extraction, as recommended by the World Federation of Hemophilia 2
  • Pre-operative preparation includes factor replacement to achieve 50-100% factor activity, and tranexamic acid 10 mg/kg IV immediately before extraction, and post-operative care includes continuing factor replacement for 2-8 days, and tranexamic acid 10 mg/kg IV 3-4 times daily for 2-8 days, and avoiding NSAIDs, using acetaminophen/codeine for pain control instead, as recommended by the World Federation of Hemophilia 2
  • Regular dental check-ups every 3-6 months, early intervention for caries, fluoride applications, pit and fissure sealants, and diet counseling to reduce caries risk are recommended for patients with hemophilia, as suggested by the World Federation of Hemophilia 2

Monitoring and Follow-up

  • Regular monitoring of aPTT and factor VIII levels is recommended, monthly for the first six months and every 2-3 months up to 12 months, to assess treatment response and adjust therapy as needed, as recommended by the National Hemophilia Foundation and the American Society of Hematology 8, 2
  • Genetic testing is indicated for family planning, confirmation of diagnosis in unclear cases, and carrier testing for female relatives, with a strength of evidence level of high, according to the National Society of Genetic Counselors 9

Complications and Emergency Care

  • Signs of bleeding complications that require immediate attention include continuous oozing despite pressure, expanding hematoma, pain not controlled by analgesics, and difficulty swallowing or breathing, as noted by the World Federation of Hemophilia 2
  • For inadequate hemostasis, the World Federation of Hemophilia suggests switching to an alternative bypassing agent if first-line treatment fails, and for severe bleeding, considering recombinant Factor VIIa (rFVIIa) or Activated Prothrombin Complex Concentrates (aPCC) as first-line treatment, with aPCC dosed at 50-100 IU/kg every 8-12 hours (maximum 200 IU/kg/day) 2, 8
  • Tranexamic acid is contraindicated with aPCC, and delayed treatment initiation, inadequate dosing or duration of bypassing agents, failure to switch agents when response is inadequate, and not initiating immunosuppressive therapy immediately after diagnosis can lead to poor outcomes, as warned by the American Society of Hematology and the International Society on Thrombosis and Haemostasis 2